Comparative effectiveness of external therapies of traditional Chinese medicine and surgical treatments in pain management of postherpetic neuralgia

A protocol for a systematic review and network meta-analysis

Zhengqi Pan, MDa, Shijie Huang, MDa, Tingting Ma, MDa, Rongli Yuan, MDm, Mengjing Wang, MDm, Rui Luo, MDm, Maogui Yu, MDm, Wuyu Li, MDm, Ao Zhang, PhDm, Jie Wu, MDm,*

Abstract

Background: As the most common long-term complication of herpes zoster (HZ), postherpetic neuralgia (PHN) is characterized by chronic, persistent, and debilitating neuropathic pain. PHN seriously harms human health and currently becomes a topic of clinical importance. To date, the common methods of pain management in PHN include external therapies of traditional Chinese medicine and surgical treatments. However, there is no high-quality or direct evidence of their comparative effectiveness. This review aims to provide a network meta-analysis to compare the efficacy of external therapies of traditional Chinese medicine and surgical treatments in the pain management of PHN.

Methods: Databases such as PubMed, Cochrane Central Register of Controlled Trials, EMBASE, China National Knowledge Infrastructure, China Biology Medicine Disc will be searched for relevant randomized controlled trials to obtain literatures on the treatment of PHN with external therapies of traditional Chinese medicine and surgical treatments, and clinical randomized controlled trials will be screened out from their inception to August 5, 2022. The participant intervention comparator outcomes of this study are as flowing: P, patients with PHN; I, external therapies of traditional Chinese medicine and surgical treatments; C, no treatment, pharmacological placebo, treatment as usual or sham acupuncture groups; O, primary outcome is pain intensity, and secondary outcomes are onset of pain relief time, quality of life, therapeutic effective rate and reverse effects. Cochrane Risk of Bias Tool will be used in assessing literature’s quality. Network meta-analyses will be conducted to generate estimates of comparative effectiveness of each intervention class and rankings of their effectiveness, in terms of pain management.

Result: This systematic review and network meta-analysis will provide evidence of the efficacy of different therapeutic methods for pain management in PHN, to show which forms of therapy are more commonly used with higher effectiveness.

Discussion: The results will systematically provide suggestions for medical practitioners to choose effective, time-saving and economical pain management method for PHN.

Abbreviations: HZ = herpes zoster, PHN = Postherpetic neuralgia, PRISMA = Preferred reporting items for systematic reviews and meta-analyses protocols.

Keywords: external therapies of traditional Chinese medicine, network meta-analysis, pain alleviation, postherpetic neuralgia, randomized controlled trial, surgical treatments, systematic review

ZP and SH have contributed equally to this work.

This project is funded by Project of Sichuan Science and Technology Department in 2021: 2021YFS0038 and Project of Sichuan and Technology Department in 2014: 2014SZ0152. The sponsors are not involved in design, execution, or writing the study.

The authors have no conflicts of interest to disclose.

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

No additional data are available.

PROSPERO registration number: CRD42022361896.

The protocol of the systematic review does not require ethical approval because it does not involve humans. This article will be published in peer-reviewed journals and presented at relevant conferences.

Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, China; School of Chinese Medicine, School of Integrated Chinese and Western Medicine, Nanying University of Chinese Medicine, Nanjing, Jiangsu Province, China.

Correspondence: Jie Wu, Hospital of Chengdu University of Traditional Chinese Medicine, No. 39 Shi-er-qiao Road, 610072 Chengdu, Sichuan Province, China (e-mail: wujiejiaoshou@163.com).

Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Pan Z, Huang S, Ma T, Yuan R, Wang M, Luo R, Yu M, Li W, Zhang A, Wu J. Comparative effectiveness of external therapies of traditional Chinese medicine and surgical treatments in pain management of postherpetic neuralgia: A protocol for a systematic review and network meta-analysis. Medicine 2022;101(43):e31517.

http://dx.doi.org/10.1097/MD.0000000000031517

Received: 3 October 2022 / Accepted: 4 October 2022
1. Introduction

Postherpetic neuralgia (PHN) is the main complication caused by Herpes Zoster (HZ). PHN is a long-lasting and difficult-to-treat disease characterized by chronic, persistent, and debilitating neuropathic pain as the main symptom. Moreover, patients with PHN often suffer from allodynia, hyperalgesia, and abnormal sensations within the affected dermatome or beyond the dermatomal margins. The current incidence of HZ in North America, Europe, and the Asia-Pacific region ranges from 3 to 5/1000 person-years, of which 6% to 30% will develop PHN; among HZ patients over 50 years old, 60% to 70% will develop PHN, and the incidence and treatment cost of PHN increase with age. PHN severely reduces the quality of life of patients and imposes a great economic burden on human society worldwide; therefore, it is important to find the rational and effective medical option for PHN.

Currently, surgical treatment is a new trend in the clinical strategy of PHN pain treatment, which includes minimal invasive surgery, nerve block, intrathecal drug injection, pulsed-radiofrequency. However, there are more or less problems with these treatments, such as limited efficacy, serious adverse reactions, and high cost. For example, the nerve block treatment often leads to some complications, such as hemorrhage, hematoma, pneumothorax, nerve injury, infection, etc. Patients with PHN are often frail and have multiple comorbidities; therefore, it becomes even more important to minimize the side effects of interventions.

External therapies of traditional Chinese medicine such as acupuncture, moxibustion, acupoint injection, have been showing its significant therapeutic effects in pain management. In many countries such as China, Japan, and Italy, in addition to the above pharmacological interventions, external therapies of traditional Chinese medicine are widely applied in pain management of PHN. There are many clinical and experimental studies have reported the therapeutic effects of external therapies of traditional Chinese medicine in treating PHN; in clinical practice, external therapies of traditional Chinese medicine have been identified as an important method with promising results in relieving patient’s pain with tiny adverse reactions. External therapies of traditional Chinese medicine appears to be an attractive alternative to other intervention as a first-line treatment due to its comparatively fewer and less severe side-effects.

Despite both external therapies of traditional Chinese medicine and surgical treatments being commonly used in treating PHN, few studies have directly compared them and the previous systematic reviews only evaluated the treatment of PHN with external therapies of traditional Chinese medicine and surgical treatments separately. This study aims to compare the efficacy of external therapies of traditional Chinese medicine and surgical treatments in the pain management of PHN through a network meta-analysis; external therapies of traditional Chinese medicine and surgical treatments will be ranked in order to determine the most effective methods, which will provide evidence for choosing certain therapeutic strategies in the pain management of PHN.

2. Method

This systematic review protocol has been registered on PROSPERO with number CRD42022361896 (https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordId=361896). This protocol will be reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses protocols (PRISMA) and this network meta-analysis will be conducted and reported in accordance with PRISMA extension version (PRISMA-NMA). We will also apply the International Society for Pharmacoeconomics and Outcomes Research Indirect Treatment Comparison/Network Meta-Analysis Study Questionnaire to Assess Relevance and Credibility to Inform Health Care Decision-Making to our study to aid the interpretation of clinicians and other healthcare decision-makers.

2.1. Eligibility criteria

2.1.1. Population. Participants with PHN, regardless of age, sex or ethnicity, were included in this study. Referring to previous studies, PHN is defined as pain persisting for more than 1 month after the skin lesions caused by HZ have resolved, or any of the above criteria included into the literature.

2.1.2. Interventions. The systematic review will focus on interventions which are intended to relieve pain in patients with PHN using either external therapies of traditional Chinese medicine and surgical treatments; among which, the surgical treatments are derived from the first-line treatments in the recent PHN guidelines and consensus, including minimal invasive surgery, nerve block, intrathecal drug injection, pulsed-radiofrequency.

2.1.3. Comparators. There are a number of types of comparator conditions which will be eligible for inclusion in the network of evidence. The types of control conditions may include no treatment, pharmacological placebo, treatment as usual or sham acupuncture groups. Furthermore, different types of external therapies of traditional Chinese medicine and surgical treatments may also be directly compared.

2.1.4. Outcomes. The primary outcome in this study will be pain intensity, which is measured by the Visual Analogue Scale, Numerical Rating Scale, as well as several other scales for measuring pain.

The secondary outcome will include onset of time for pain relief, quality of life, therapeutic effective rate and reverse effects.

2.1.5. Study designs. The systematic review will only include randomized controlled trials. These trials must have a sample size of at least 20 participants per condition and must involve interventions delivered for a minimum of 4 weeks. To reduce heterogeneity, crossover trials will be excluded. Studies making within-class comparisons only (e.g., ordinary acupuncture versus electroacupuncture) will also be excluded. Finally, studies must be reported in English or in Chinese.

2.2. Information sources and search strategy

We will search PubMed, Cochrane Central Register of Controlled Trials, EMBASE, China National Knowledge Infrastructure, China Biology Medicine Disc from inception to August 5, 2022 with the language restriction of English and Chinese. Randomized controlled trials that exhibited the effective therapies of PHN will be selected. The search keywords contain PHN (e.g., postherpetic neuralgia, herpetic pain), first-line surgical treatments for treating PHN (e.g., minimal invasive surgery, nerve block, intrathecal drug injection, pulsed-radiofrequency), external therapies of traditional Chinese medicine (e.g., acupuncture, acupoint injection, electroacupuncture, moxibustion, cupping, tuina). The search strategy for PubMed is shown in Table 1, and other electronic databases will be searched with the same strategy.

2.3. Data collection and analysis

2.3.1. Study selection. All reviewers will receive professional training to understand the objective and process of the review before the selection of studies. Literature search results will be imported into ENDNOTE X8 software. The duplicates will be removed. For studies that have been updated, the older 1 will be
will be used for analysis. For continuous data, a mean difference
of external therapies of TCM will be classified according to the type of acupuncture
intervention, type of surgical treatments or type of control
condition employed, where applicable. The type of surgical
treatments included in this study are those used as first-line
treatment, as indicated by the guidelines for PHN.[5,21] The type of
external therapies of TCM will be classified according to the
type of acupuncture intervention. Control conditions
will be classified as active or passive. Passive control conditions
are those where no intervention is applied, while active control
conditions involve some intervention (e.g., placebo, usual care).

2.3.3. Classification of arms. Classification of arms will be
carried out at the data extraction stage. The arms of each
trial will be classified according to the type of acupuncture
intervention, type of surgical treatments or type of control
condition, as indicated by the guidelines for PHN.[5,21] The type of
external therapies of TCM will be classified according to the
different types reviewed by a published article,[22] in their review
of interventions for the treatment of PHN. These classifications
will include ordinary acupuncture, electro-acupuncture,
auricular acupuncture, acupuncture injection, moxibustion,
bloodletting, cupping, fire needle, and plum blossom needle,
which may include combinations of the any of the previously
listed types of acupuncture intervention. Control conditions
will be classified as active or passive. Passive control conditions
are those where no intervention is applied, while active control
conditions involve some intervention (e.g., placebo, usual care).

A network diagram will be generated to visualize the evidence
available for analysis, both in terms of possible pairwise
comparisons and the volume of evidence underlying each of
these comparisons. The reference node will contain active
control conditions. Different combinations of interventions will
be included as separate nodes. A network diagram will be
generated to visualize the evidence available for analysis, both
in terms of possible pairwise comparisons and the volume of
evidence underlying each of these comparisons.[24] The reference
node will contain active control conditions. Different
combinations of interventions will be included as separate
nodes.

2.3.4. Risk of bias. For studies which are passed through the
full-text screening stage, risk of bias will be assessed independently by 2 reviewers (ZQP and SJH) using the
standard Cochrane risk of bias tool in Covidence which assesses sequence generation and allocation concealment, blinding of
participants and personnel, blinding of outcome assessors and incompleteness of the outcome data and whether reporting
appears to be selective.[23] Discrepancies will be identified and
resolved by consulting a third reviewer (JW).

2.3.5. Assessment of transitivity. A table of trial characteristics
which may act as effect modifiers will be compiled from the
data collected (as specified above) to aid in the assessment of
the assumption of transitivity. Potential effect modifiers
include total study duration, setting, age distribution, gender
distribution, ethnicity distribution, patient comorbidity history
and past/present medication use.[22,27]

2.4. Data synthesis

The main objective of this data synthesis is to compare the
effectiveness of different interventions focused on external ther-
apies of traditional Chinese medicine and surgical treatments.
Network meta-analysis is useful for achieving this objective
because it allows indirect estimates to be computed where lit-
tle direct evidence exists. Few studies have directly compared
effects of different interventions focused on external therapies of traditional Chinese medicine and surgical treatments.
Network meta-analysis is useful for achieving this objective
because it allows indirect estimates to be computed where lit-
tle direct evidence exists. Few studies have directly compared
effects of different interventions focused on external therapies of traditional Chinese medicine and surgical treatments.
Network meta-analysis is useful for achieving this objective
because it allows indirect estimates to be computed where lit-
tle direct evidence exists. Few studies have directly compared

2.4.1. Pairwise meta-analysis. Where head-to-head data is
available, exploratory pairwise meta-analyses will be conducted.
These will be run using a random-effects model. The individual
and pooled effect sizes will be visualized using Forrest plots.
Funnel plots and Egger’s test will be employed to examine
publication bias and the effects of small studies.[24]

excluded, or can be used as supplementary data in further research.
Titles and abstracts will be screened independently by 2 reviewers
(ZQP and SJH). Full texts will be obtained for eligible studies and
will be screened independently (ZQP and SJH). Discrepancies will
be resolved through discussion, or by consulting a third reviewer
(AZ). The procedures of study selection will be performed in
accordance with the Preferred Reporting Items for Systematic
reviews and Meta-Analysis flow chart (as shown in Fig. 1).

2.3.2. Data extraction and analysis. Two reviewers (ZQP and
SJH) will establish a sheet using Microsoft Excel 2010, pilot
and refine this form using 10 initial studies. After the form has
been developed, the 2 reviewers will extract data from the text
and figure/table independently, including: general information
e.g., author, year of publication, country where the study was
conducted, study period, original inclusion criteria); participants
e.g., age, gender, sample size); details about intervention (e.g.,
surgical treatments type, administration method, duration of
study, follow-up time, acupuncture parameters, acupuncture
points); study design (e.g., randomization, blinding and
allocation concealment); outcomes and adverse reactions.

Discrepancies will be identified and resolved through discus-
sion (with a third reviewer where necessary), or by consulting a
third reviewer (JW). We first try to extract numerical data from
tables, text or figures. If these are not reported, we will extract
data from graphs using digital ruler software. In case data is
not reported or unclear, we will attempt to contact authors by
e-mail (max. 2 attempts).

WinBUGS and Stata 15.1 will be used in data analysis.[21] For
dichotomous data, a risk ratio with 95% confidence intervals
will be used for analysis. For continuous data, a mean difference
or a standard mean difference with 95% confidence intervals
will be used for analysis.

### Table 1

| Number | Search terms |
|--------|--------------|
| #1     | * Postherpetic neuralgia* \[exploded MeSH\] OR *Postherpetic neuralgia* \[Title/Abstract\] OR *Post herpetic neuralgia* \[Title/Abstract\] OR *Post herpetic neuralgia* \[Title/Abstract\] OR *PHN* \[Title/Abstract\] OR *post herpetic pain* \[Title/Abstract\] OR *post herpetic pain* \[Title/Abstract\] |
| #2     | * Neuralgia* \[explicated MeSH\] OR *Pain* \[explicated MeSH\] OR * neuralgia* \[Title/Abstract\] OR * Pain* \[Title/Abstract\] AND * (Herpes zoster* \[explicated MeSH\] OR * Zoster* \[Title/Abstract\] OR * Shingles* \[Title/Abstract\] OR * Zona* \[Title/Abstract\] OR * VZV* \[Title/Abstract\] OR *HZ* \[Title/Abstract\] |
| #3     | #1 OR #2 |
| #4     | * Minimal invasive surgery* \[Mesh\] OR * Nerve block* \[Mesh\] OR * Intrathecal drug injection* \[Mesh\] OR * Pulsed-radiofrequency* \[Mesh\] OR * MIS* \[Title/Abstract\] OR * Tiny traumatic interventional treatment* \[Title/Abstract\] OR * Micronvasive intervention* \[Title/Abstract\] OR * Minimally invasive technic* \[Title/Abstract\] OR * MIT* \[Title/Abstract\] OR * AS-N* \[Title/Abstract\] OR * CPNB* \[Title/Abstract\] OR * Nerveblock* \[Title/Abstract\] OR * Intraspinal injection* \[Title/Abstract\] OR * Pulsed RF* \[Title/Abstract\] OR * PRF* \[Title/Abstract\] OR * Pulse RF* \[Title/Abstract\] |
| #5     | *Acupuncture* \[Mesh\] OR * Cupping* \[Title/Abstract\] OR * Moxibustion* \[Title/Abstract\] OR *Chinese External Medicine* \[Title/Abstract\] OR *Electroacupuncture* \[Title/Abstract\] OR *Fire Needle* \[Title/Abstract\] OR *Bloodletting* \[Title/Abstract\] OR *Acupuncture injection* \[Title/Abstract\] OR *Pulm blossom needle* \[Title/Abstract\] |
| #6     | #4 OR #5 |
| #7     | *Randomized Controlled Trial* \[Title/Abstract\] OR * Controlled Clinical Trial* \[Title/Abstract\] OR *Clinical Trial* \[Title/Abstract\] OR *RCT* \[Title/Abstract\] |
| #8     | #3 AND #6 AND #7 |

H2 = herpes zoster, PHN = postherpetic neuralgia.
2.4.2. **Network meta-analysis.** If the assumption of transitivity is deemed to be met, random-effects Network meta-analyses will be conducted within a Bayesian framework using vague priors. These analyses will be carried out in line with the framework set out by Dias et al.[29] Estimates of the pairwise comparison of each intervention in the network will be presented in tables in the final manuscript, as will rankings demonstrating the probability of each intervention producing the best outcome. These rankings will be presented with mean ranks, 95% credible intervals and the surface under the cumulative ranking curve. Convergence will be assessed by checking if the Gelman-Rubin statistic is less than 1.1.[30,31]

2.4.3. **Assessment of inconsistency, heterogeneity and quality of the evidence.** Statistical heterogeneity will be assessed for each pairwise meta-analysis using the $I^2$ and $\tau^2$ statistics in line with the Cochrane guidelines. Since the included studies are likely to consist of a mixture of 2-arm and multi-arm studies, it is necessary to consider design inconsistency as well as loop inconsistency. This will be achieved by applying a design-by-treatment interaction model. If inconsistency is indicated in the network, any closed loops within the network will be assessed.[32]

The quality of the evidence used in this study will be assessed using the GRADE 4-step approach for rating the quality of treatment effect estimates from network meta-analysis.[33]

2.4.4. **Additional analyses.** Exploratory analyses will be carried out, where there is a sufficient amount of information available to do so. These analyses will focus on the covariates the age distribution, gender distribution and ethnicity distribution. Network meta-regressions will be conducted to individually examine the influence of these covariates on effect size estimates. Finally, sensitivity analyses will be conducted to assess the influence of the use of specific treatments in the network rather than classes and trial quality.

3. **Discussion**

With the aging of the population and people’s living habits, the incidence of PHN is on the rise.[2,34,35] Meanwhile, PHN is notoriously difficult to treat; complete resolution of symptoms is rare, and only less than 50% of PHN patients can achieve noteworthy pain relief.[36] PHN seriously disturbs the patient’s sleep, produce anxiety, depression and other adverse psychology; in further, PHN affects patient’s quality of life, and brings enormous economic pressure.[37] Therefore, solving the treatment difficulties of PHN is beneficial to the development of mankind’s health career.

We hope that through this study, direct and indirect evidence on the efficacy of external therapies of traditional Chinese medicine and surgical treatments for the pain management of PHN.
PHN will be found, and the rankings will be provided by using a network meta-analysis. This study aims to provide reliable evidence-based information for medical practitioners to choose different therapeutic strategies in the clinical treatment of PHN; at the same time, this study is also helpful for the design treatment guidelines and the adjustment of health insurance plans.

**Author contributions**

Conceptualization: Zhengqi Pan, Shijie Huang.

Data curation: Zhengqi Pan, Shijie Huang, Tingting Ma.

Formal analysis: Zhengqi Pan, Shijie Huang

Investigation: Jie Wu, Tingting Ma.

Methodology: Jie Wu.

Project administration: Zhengqi Pan.

Resources: Rongli Yuan, Rui Luo.

Software: Rongli Yuan, Mengjing Wang, Tingting Ma.

Supervision: Jie Wu.

Validation: Mengjing Wang, Maogui Yu, Wuyu Li, Ao Zhang.

Writing – original draft: Zhengqi Pan, Shijie Huang.

Writing – review & editing: Zhengqi Pan, Shijie Huang.

**Contributorship statement**

I certify that neither this manuscript nor I with substantially similar content under my authorship has been published or is being considered for publication elsewhere (except as indicated in an attachment). I have access to any data upon which the manuscript is based and will provide such data upon request to the editors or their assignees.

**References**

[1] Johnson RW, Rice ASC. Postherpetic neuralgia. NEJM. 2014;371:1526–33.

[2] Malec-Milewska M, Sękowska A, Kołda L, et al. Postherpetic neuralgia-epidemiology, pathomechanism, risk factors, symptoms, treatment. Personal experience with treatment of patients with post herpetic neuralgia. Ból. 2012;1:7.

[3] Boltonova A, Mehta ND. Interventional management of chronic visceral pain syndromes. Postherpetic Neuralgia. 2021;57:14–7.

[4] Aydel M, Tuncer US, Sęgi K, et al. Immunological mechanism of postherpetic neuralgia and effect of pregabalin treatment on the mechanism: a prospective single-arm observational study. Korean J Pain. 2021;34:463–70.

[5] Kim SR, Khan F, Ramirez-Fort MK, et al. Varicella zoster: an update on current treatment options and future perspectives. Expert Opin Pharmacother. 2014;15:61–71.

[6] Hoshi S, Saposco X, Shono A, et al. Cost-effectiveness of Recombinant Zoster Vaccine (RZV) and Varicella Vaccine Live (VVL) against herpes zoster and post-herpetic neuralgia among adults aged 65 and over in Japan. Vaccine. 2019;37: 3588–97.

[7] Finnerup NB, Otto M, McQuay HJ, et al. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain. 2005;118:305–305.

[8] Indirect assessment of the effectiveness and safety of gabapentinoid drugs in the treatment of neuropathic pain. Basic Clin Pharmacol Toxicol. 2005;96:399–409.

[9] Zorzoli E, Pica F, Masetti G, et al. Herpes zoster in frail elderly patients: prevalence, impact, management, and preventive strategies. Aging Clin Exp Res. 2018;30:693–702.

[10] Lee IS, Lee H, Chen YH, et al. Epidemiology and treatment of herpes zoster. J Pain Res. 2020;13: 367–76.

[11] Nielsen A, Duske J, Taylor-Swanson L, et al. Acupuncture therapy as an evidence-based nonpharmacologic strategy for comprehensive acute pain care: the academic consortium pain task force white paper update. Pain Med. 2022;12:89–95.

[12] Taguchi R. Acupuncture anesthesia and analgesia for clinical acute pain in Japan. Evid Based Complement Alternat Med. 2008;5:153–8.

[13] Feng Q, Zhou HF. Clinical Research of Fire-Needle Acupuncture combined with cupping treating herpes zoster and postherpetic neuralgia. Niger J Clin Pract. 2019;12:11–12.

[14] Urasu T, Tomodona M, Manzoli L, et al. Acupuncture for the treatment of severe acute pain in Herpes Zoster: results of a nested, open-label, randomized trial in the VZV Pain Study. BMC Complement Altern Med. 2011;11:1–8.

[15] Singh R, Silverberg NB, Silverberg JJ. The treatment of herpes zoster and post zoster neuralgia with acupuncture and western herbs in Chinese medicine. Chin J Integr Med. 2015;19:284–87.

[16] Zou J, Dong X, Wang K, et al. Electroacupuncture inhibits autophagy of neuron cells in postherpetic neuralgia by increasing the expression of miR-223-3p. Biomed Res Int. 2021;2018:37–39.

[17] Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;13:123–5.

[18] Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162:777–84.

[19] Jansen JP, Trikalinos T, Cappelleri JC, et al. Indirect treatment comparison/network meta-analysis study questionnaire to assess relevance and credibility in reducing health care decision making: an ISPOR-AMCP-NPCG Good Practice Task Force Report. Value Health. 2014;17:157–73.

[20] Pei W, Zeng J, Lu L, et al. Is acupuncture an effective post herpetic neuralgia treatment? A systematic review and meta-analysis. J Pain Res. 2019;12:2153–2163.

[21] Gross GE, Eisert L, Doerr HW, et al. S2k guidelines for the diagnosis and treatment of herpes zoster and postherpetic neuralgia. J Dtsch Dermatol Ges. 2020;18:55–79.

[22] Wei S, Li X, Wang H, et al. Analysis of the risk factors for post herpetic neuralgia. Dermatol J. 2019;23:1–8.

[23] Lunn DJ, Thomas A, Best N, et al. WinBUGS—a Bayesian modeling framework: concepts, structure, and extensibility. Stat Comput. 2000;12:51–4.

[24] Chaimani A, Higgins JPT, Mavridis D, et al. Graphical tools for network meta-analysis in STATA. PLoS One. 2013;8:e67654.e67654.

[25] Higgins JPT, Altman DG, Sterne JAC. Cochrane Handbook Rev Interv 5.00. Chapter 8: Assessing risk of bias in included studies. 2011;7:56–9.

[26] Chaimani A, Caldwell DM, Li T, et al. Additional considerations are required when preparing a protocol for a systematic review with multiple interventions. J Clin Epidemiol. 2017;83:6–74.

[27] Salanti G. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Res Synth Methods. 2012;3:80–123.

[28] Borenstein M, Hedges LV, Higgins JPT, et al. Introduction to meta-analysis. John Wiley & Sons, 2009;2009.

[29] Dias S, Sutton AJ, Ades AE, et al. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network Meta-analysis of randomized controlled trials. Med Decis Mak. 2011;33:607–617.

[30] Gelman A, Rubin DB. Inference from iterative simulation using multiple sequences. Stat Sci. 1992;7:457–472.

[31] Brooks SP, Gelman A. General methods for monitoring convergence of iterative simulations. J Comput Graph Stat. 1998;7:434–455.

[32] Jackson D, Barrett JK, Rice S, et al. A design-by-treatment interaction model for network meta-analysis with random inconsistency effects. Stat Med. 2019;38:5052–5070.

[33] Brignardello-Petersen R, Bonner A, Alexander PE, et al. Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis. J Clin Epidemiol. 2018;93:36–44.

[34] Bennett GW, Watson C. Herpes zoster and postherpetic neuralgia: past, present and future. Pain Res Manag. 2016;3:21–24.

[35] Boltonova A, Mehta N D. Postherpetic Neuralgia. Interventional Management of Chronic Visceral Pain Syndromes. Elsevier; 2021:149–55.

[36] Schutzer WJ, Farquhar SP. Post-herpetic neuralgia - a review of current management and future directions. Expert Opin Pharmacother. 2017;18:1739–30.

[37] Lee DH, Park JE, Yoon DM, et al. Factors associated with increased risk for clinical insomnia in patients with postherpetic Neuralgia: a Retrospective Cross-Sectional Study. Pain Medicine. 2016;17:1917–22.